Study of BR with OR for untreated marginal zone lymphoma
Part of Cancer clinical trials.
This study tests a combination of two drugs (BR and OR) for people with marginal zone lymphoma that hasn't been treated yet or has come back after local therapy. The goal is to see if the combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of B-cell lymphoma called marginal zone lymphoma that has a protein called CD20 on the cancer cells.
- You must have at least one tumor that can be measured on a scan or exam.
- If you have had any prior treatment, it must have been only local (like surgery or radiation) and your disease has since come back or gotten worse.
- You need to be in fairly good health, with your liver, kidneys, and blood counts meeting certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This trial tests a new combination of two drugs (ibrutinib and rituximab) for people with marginal zone lymphoma that has not responded to other treatments. The goal is to see if this combination can help shrink the lymphoma and improve outcomes.
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
Hear when a new Marginal Zone Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.